Pathological Ventricular Remodeling: Mechanisms Part 1 of 2

Despite declines in heart failure morbidity and mortality with current therapies, rehospitalization rates remain distressingly high, substantially affecting individuals, society, and the economy. As a result, the need for new therapeutic advances and novel medical devices is urgent. Disease-related left ventricular remodeling is a complex process involving cardiac myocyte growth and death, vascular rarefaction, fibrosis, inflammation, and electrophysiological remodeling. Because these events are highly interrelated, targeting a single molecule or process may not be sufficient. Here, we review molecular and cellular mechanisms governing pathological ventricular remodeling.

[1]  G. Filippatos,et al.  Hemodynamic, echocardiographic, and neurohormonal effects of istaroxime, a novel intravenous inotropic and lusitropic agent: a randomized controlled trial in patients hospitalized with heart failure. , 2008, Journal of the American College of Cardiology.

[2]  Yasushi Matsumura,et al.  The role of autophagy in cardiomyocytes in the basal state and in response to hemodynamic stress , 2007, Nature Medicine.

[3]  M. Miragoli,et al.  Myofibroblasts Induce Ectopic Activity in Cardiac Tissue , 2007, Circulation research.

[4]  J. Funder Reconsidering the Roles of the Mineralocorticoid Receptor , 2009, Hypertension.

[5]  P. Mulder,et al.  Aldosterone synthase inhibition improves cardiovascular function and structure in rats with heart failure: a comparison with spironolactone. , 2008, European heart journal.

[6]  J. Daubert,et al.  The effect of cardiac resynchronization on morbidity and mortality in heart failure. , 2005, The New England journal of medicine.

[7]  A. Jánosi,et al.  Rosuvastatin in older patients with systolic heart failure. , 2007, The New England journal of medicine.

[8]  W. Koch,et al.  Targeting GRK2 by gene therapy for heart failure: benefits above β-blockade , 2012, Gene Therapy.

[9]  Arantxa González,et al.  Usefulness of Serum Carboxy-Terminal Propeptide of Procollagen Type I in Assessment of the Cardioreparative Ability of Antihypertensive Treatment in Hypertensive Patients , 2001, Circulation.

[10]  A. Varki,et al.  Evidence for a novel human-specific xeno-auto-antibody response against vascular endothelium. , 2009, Blood.

[11]  Joseph A. Hill,et al.  Pathological Ventricular Remodeling: Therapies Part 2 of 2 , 2013, Circulation.

[12]  E. Olson,et al.  Hypertrophy of the heart: a new therapeutic target? , 2004, Circulation.

[13]  C. Long,et al.  The cardiac fibroblast: therapeutic target in myocardial remodeling and failure. , 2005, Annual review of pharmacology and toxicology.

[14]  Joseph A. Hill,et al.  Electrophysiological remodeling in heart failure. , 2010, Journal of molecular and cellular cardiology.

[15]  D. Sane,et al.  Statin Therapy May Be Associated With Lower Mortality in Patients With Diastolic Heart Failure: A Preliminary Report , 2005, Circulation.

[16]  Nan Jiang,et al.  Metabolic stress-induced activation of FoxO1 triggers diabetic cardiomyopathy in mice. , 2012, The Journal of clinical investigation.

[17]  Karl-Ludwig Laugwitz,et al.  Postnatal isl1+ cardioblasts enter fully differentiated cardiomyocyte lineages , 2005, Nature.

[18]  E. Neilson,et al.  Evidence that fibroblasts derive from epithelium during tissue fibrosis. , 2002, The Journal of clinical investigation.

[19]  M. Al-mallah,et al.  Adult bone marrow-derived cells for cardiac repair: a systematic review and meta-analysis. , 2007, Archives of internal medicine.

[20]  J. Oss,et al.  PROPHYLACTIC IMPLANTATION OF A DEFIBRILLATOR IN PATIENTS WITH MYOCARDIAL INFARCTION AND REDUCED EJECTION FRACTION , 2002 .

[21]  D. Sica,et al.  Therapeutic perspectives in hypertension: novel means for renin–angiotensin–aldosterone system modulation and emerging device-based approaches , 2011, European heart journal.

[22]  M. Drazner,et al.  Does load-induced ventricular hypertrophy progress to systolic heart failure? , 2005, American journal of physiology. Heart and circulatory physiology.

[23]  Y. Taenaka,et al.  Influence of prolonged ventricular assistance on myocardial histopathology in intact heart. , 1996, The Annals of thoracic surgery.

[24]  Scott T Acton,et al.  Automated image analysis identifies signaling pathways regulating distinct signatures of cardiac myocyte hypertrophy. , 2012, Journal of molecular and cellular cardiology.

[25]  S. Russell,et al.  The gene expression profile of patients with new-onset heart failure reveals important gender-specific differences. , 2010, European heart journal.

[26]  D. Levy,et al.  Sex differences in cardiac adaptation to isolated systolic hypertension. , 1993, The American journal of cardiology.

[27]  Karl Swedberg,et al.  Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial , 2003, The Lancet.

[28]  J. Richardson,et al.  Cardiac autophagy is a maladaptive response to hemodynamic stress. , 2007, The Journal of clinical investigation.

[29]  D. Torella,et al.  Resident human cardiac stem cells: role in cardiac cellular homeostasis and potential for myocardial regeneration , 2006, Nature Clinical Practice Cardiovascular Medicine.

[30]  Chad E. Grueter,et al.  A Cardiac MicroRNA Governs Systemic Energy Homeostasis by Regulation of MED13 , 2012, Cell.

[31]  V. Regitz-Zagrosek,et al.  Regression of Myocardial Hypertrophy After Aortic Valve Replacement: Faster in Women? , 2009, Circulation.

[32]  A. Maseri,et al.  Age-related increase in mortality among patients with first myocardial infarctions treated with thrombolysis. The Investigators of the Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico (GISSI-2). , 1993, The New England journal of medicine.

[33]  M. Kinoshita,et al.  Relationship between transcardiac extraction of aldosterone and left ventricular remodeling in patients with first acute myocardial infarction: extracting aldosterone through the heart promotes ventricular remodeling after acute myocardial infarction. , 2001, Journal of the American College of Cardiology.

[34]  K. Youker,et al.  Therapeutic plasma exchange a potential strategy for patients with advanced heart failure , 2010, Journal of clinical apheresis.

[35]  Antti Tanskanen,et al.  Key pathways associated with heart failure development revealed by gene networks correlated with cardiac remodeling. , 2008, Physiological genomics.

[36]  V. Roger,et al.  Trends in prevalence and outcome of heart failure with preserved ejection fraction. , 2006, The New England journal of medicine.

[37]  R. Gomer,et al.  Bone marrow-derived fibroblast precursors mediate ischemic cardiomyopathy in mice , 2006, Proceedings of the National Academy of Sciences.

[38]  D. May,et al.  Vascular Endothelial Growth Factor–Induced Neovascularization Rescues Cardiac Function But Not Adverse Remodeling at Advanced Ischemic Heart Disease , 2012, Arteriosclerosis, thrombosis, and vascular biology.

[39]  Stefanie Dimmeler,et al.  Impaired CXCR4 Signaling Contributes to the Reduced Neovascularization Capacity of Endothelial Progenitor Cells From Patients With Coronary Artery Disease , 2005, Circulation research.

[40]  C. Long,et al.  Angiotensin II stimulates cardiac myocyte hypertrophy via paracrine release of TGF-beta 1 and endothelin-1 from fibroblasts. , 1998, Cardiovascular research.

[41]  A. Louis,et al.  Clinical Trials Update: CAPRICORN, COPERNICUS, MIRACLE, STAF, RITZ‐2, RECOVER and RENAISSANCE and cachexia and cholesterol in heart failure. Highlights of the Scientific Sessions of the American College of Cardiology, 2001 , 2001, European journal of heart failure.

[42]  D. Cox,et al.  Cardiac Myosin Activation: A Potential Therapeutic Approach for Systolic Heart Failure , 2011, Science.

[43]  G. Booz,et al.  Angiotensin II is mitogenic in neonatal rat cardiac fibroblasts. , 1993, Circulation research.

[44]  Y. Tsujimoto,et al.  Another way to die: autophagic programmed cell death , 2005, Cell Death and Differentiation.

[45]  R. Henkelman,et al.  Electrical remodelling precedes heart failure in an endothelin-1-induced model of cardiomyopathy. , 2011, Cardiovascular research.

[46]  Henry Krum,et al.  Direct renin inhibition in addition to or as an alternative to angiotensin converting enzyme inhibition in patients with chronic systolic heart failure: rationale and design of the Aliskiren Trial to Minimize OutcomeS in Patients with HEart failuRE (ATMOSPHERE) study , 2011, European journal of heart failure.

[47]  F. Bushman,et al.  Intestinal microbiota metabolism of L-carnitine, a nutrient in red meat, promotes atherosclerosis , 2013, Nature Medicine.

[48]  Akshay S. Desai,et al.  Effect of the direct renin inhibitor aliskiren on left ventricular remodelling following myocardial infarction with systolic dysfunction. , 2011, European heart journal.

[49]  Y. Dor,et al.  Induction of Vascular Networks in Adult Organs: Implications to Proangiogenic Therapy , 2003, Annals of the New York Academy of Sciences.

[50]  Brian O'Rourke,et al.  Electrophysiological Consequences of Dyssynchronous Heart Failure and Its Restoration by Resynchronization Therapy , 2009, Circulation.

[51]  Richard T. Lee,et al.  Regeneration of the heart , 2011, EMBO molecular medicine.

[52]  W. Thomas,et al.  Non-genomic actions of aldosterone: From receptors and signals to membrane targets , 2012, Molecular and Cellular Endocrinology.

[53]  C. Tschöpe,et al.  Renin Inhibition Improves Cardiac Function and Remodeling After Myocardial Infarction Independent of Blood Pressure , 2008, Hypertension.

[54]  Manesh R. Patel,et al.  Effect of phosphodiesterase-5 inhibition on exercise capacity and clinical status in heart failure with preserved ejection fraction: a randomized clinical trial. , 2013, JAMA.

[55]  F. Sweep,et al.  Haematopoietic stem cells and endothelial progenitor cells in healthy men: effect of aging and training , 2006, Aging cell.

[56]  A. Carayon,et al.  , Brigitte Angiotensin II Receptor Blockade and Role in Cardiac Fibrosis Activation of Cardiac Aldosterone Production in Rat Myocardial Infarction : Effect of , 1999 .

[57]  A. Maseri,et al.  Age-Related Increase in Mortality among Patients with First Myocardial Infarctions Treated with Thrombolysis , 1993 .

[58]  D. Klionsky,et al.  Eaten alive: a history of macroautophagy , 2010, Nature Cell Biology.

[59]  D. Mann,et al.  Communication in the Heart: the Role of the Innate Immune System in Coordinating Cellular Responses to Ischemic Injury , 2012, Journal of Cardiovascular Translational Research.

[60]  N. Freemantle,et al.  Perindopril for elderly people with chronic heart failure: the PEP‐CHF study , 1999, European heart journal.

[61]  Lubo Zhang,et al.  Hypoxia and fetal heart development. , 2010, Current molecular medicine.

[62]  R. Shannon,et al.  Glucagon-Like Peptide-1 Increases Myocardial Glucose Uptake via p38&agr; MAP Kinase-Mediated, Nitric Oxide-Dependent Mechanisms in Conscious Dogs With Dilated Cardiomyopathy , 2010, Circulation. Heart failure.

[63]  E. Frohlich,et al.  The aging hypertensive heart: a brief update , 2008, Nature Clinical Practice Cardiovascular Medicine.

[64]  F. Cacciapaglia,et al.  Cardiovascular safety of anti-TNF-alpha therapies: facts and unsettled issues. , 2011, Autoimmunity reviews.

[65]  M. Gheorghiade,et al.  Rationale and design of the multicentre, randomized, double‐blind, placebo‐controlled Aliskiren Trial on Acute Heart Failure Outcomes (ASTRONAUT) , 2011, European journal of heart failure.

[66]  D. Mann,et al.  Inflammatory mediators and the failing heart: a translational approach. , 2003, Current molecular medicine.

[67]  S. Werns Effect of Nesiritide in Patients with Acute Decompensated Heart Failure , 2012 .

[68]  O. Kuss,et al.  Age-dependent depression in circulating endothelial progenitor cells inpatients undergoing coronary artery bypass grafting , 2003 .

[69]  M. Hopman,et al.  Preserved cardiac function after chronic spinal cord injury. , 2006, Archives of physical medicine and rehabilitation.

[70]  B. Jugdutt,et al.  Vascular remodeling during healing after myocardial infarction in the dog model: effects of reperfusion, amlodipine and enalapril. , 2002, Journal of the American College of Cardiology.

[71]  Shunichi Homma,et al.  Effect of obesity and overweight on left ventricular diastolic function: a community-based study in an elderly cohort. , 2011, Journal of the American College of Cardiology.

[72]  David L Hayes,et al.  Sustained Reverse Left Ventricular Structural Remodeling With Cardiac Resynchronization at One Year Is a Function of Etiology: Quantitative Doppler Echocardiographic Evidence From the Multicenter InSync Randomized Clinical Evaluation (MIRACLE) , 2006, Circulation.

[73]  F. Crea,et al.  Sex-related differences in myocardial remodeling. , 2010, Journal of the American College of Cardiology.

[74]  D. Klionsky,et al.  Autophagy in the Eukaryotic Cell , 2002, Eukaryotic Cell.

[75]  S. Silver,et al.  Heart Failure , 1937, The New England journal of medicine.

[76]  W. Stevenson,et al.  Characterization of the Peri-Infarct Zone by Contrast-Enhanced Cardiac Magnetic Resonance Imaging Is a Powerful Predictor of Post–Myocardial Infarction Mortality , 2006, Circulation.

[77]  G. Dorn,et al.  Mechanical Unloading Activates FoxO3 to Trigger Bnip3‐Dependent Cardiomyocyte Atrophy , 2013, Journal of the American Heart Association.

[78]  R. Kerber,et al.  Cardiac hypertrophy is not a required compensatory response to short-term pressure overload. , 2000, Circulation.

[79]  M. Simons,et al.  Growth factor-induced therapeutic angiogenesis in the heart: protein therapy. , 2005, Cardiovascular research.

[80]  Catherine A. Risebro,et al.  Thymosin β4 induces adult epicardial progenitor mobilization and neovascularization , 2007, Nature.

[81]  Jeroen J. Bax,et al.  Results of the Predictors of Response to CRT (PROSPECT) Trial , 2008, Circulation.

[82]  Xiaoxia Qi,et al.  Heart repair by reprogramming non-myocytes with cardiac transcription factors , 2012, Nature.

[83]  Mark J Post,et al.  Therapeutic angiogenesis in the heart: protect and serve. , 2007, Current opinion in pharmacology.

[84]  M. Packer,et al.  Clinical effects of beta-adrenergic blockade in chronic heart failure: a meta-analysis of double-blind, placebo-controlled, randomized trials. , 1998, Circulation.

[85]  Nicolas Servant,et al.  Ubiquinol-cytochrome-c reductase 7.2 kDa protein of mitochondrial complex III is steroid-responsive and increases in cardiac hypertrophy and hypertension. , 2007, Canadian journal of physiology and pharmacology.

[86]  Wolfgang A Linke,et al.  Sense and stretchability: the role of titin and titin-associated proteins in myocardial stress-sensing and mechanical dysfunction. , 2007, Cardiovascular research.

[87]  P. Anversa,et al.  Angiotensin II induces apoptosis of adult ventricular myocytes in vitro. , 1997, Journal of molecular and cellular cardiology.

[88]  M. Movsesian,et al.  Ca(2+)-transporting ATPase, phospholamban, and calsequestrin levels in nonfailing and failing human myocardium. , 1994, Circulation.

[89]  D. Levy,et al.  A Systematic Assessment of Causes of Death After Heart Failure Onset in the Community: Impact of Age at Death, Time Period, and Left Ventricular Systolic Dysfunction , 2011, Circulation. Heart failure.

[90]  Douglas L Packer,et al.  Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. , 2005, The New England journal of medicine.

[91]  H. Willard,et al.  X-inactivation profile reveals extensive variability in X-linked gene expression in females , 2005, Nature.

[92]  Samuel Bernard,et al.  Evidence for Cardiomyocyte Renewal in Humans , 2008, Science.

[93]  P. Vandenabeele,et al.  Molecular mechanisms of necroptosis: an ordered cellular explosion , 2010, Nature Reviews Molecular Cell Biology.

[94]  Douglas L Mann,et al.  Targeted anticytokine therapy and the failing heart. , 2005, The American journal of cardiology.

[95]  James B. Young,et al.  Clinical trials to "real-world" heart failure: applying risk stratification to deliver personalized care. , 2011, Heart failure clinics.

[96]  I. Poornima,et al.  Chronic Glucagon-Like Peptide-1 Infusion Sustains Left Ventricular Systolic Function and Prolongs Survival in the Spontaneously Hypertensive, Heart Failure–Prone Rat , 2008, Circulation. Heart failure.

[97]  K. Swedberg,et al.  Effects of oral tolvaptan in patients hospitalized for worsening heart failure: the EVEREST Outcome Trial. , 2007, JAMA.

[98]  S. Prabhu Nitric oxide protects against pathological ventricular remodeling: reconsideration of the role of NO in the failing heart. , 2004, Circulation research.

[99]  E. Olson,et al.  Cardiogenic small molecules that enhance myocardial repair by stem cells , 2008, Proceedings of the National Academy of Sciences.

[100]  D. Torella,et al.  Adult Cardiac Stem Cells Are Multipotent and Support Myocardial Regeneration , 2003, Cell.

[101]  Joseph A. Hill,et al.  Diabetic cardiomyopathy and metabolic remodeling of the heart. , 2013, Life sciences.

[102]  P. Buttrick,et al.  Reverse Remodeling With Left Ventricular Assist Devices: A Review of Clinical, Cellular, and Molecular Effects , 2011, Circulation. Heart failure.

[103]  D. Kass,et al.  Small-molecule therapies for cardiac hypertrophy: moving beneath the cell surface , 2007, Nature Reviews Drug Discovery.

[104]  Masashi Komeda,et al.  Determination of optimal duration of mechanical unloading for failing hearts to achieve bridge to recovery in a rat heterotopic heart transplantation model. , 2007, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[105]  C. H. Chen,et al.  Verapamil acutely reduces ventricular-vascular stiffening and improves aerobic exercise performance in elderly individuals. , 1999, Journal of the American College of Cardiology.

[106]  Xueli Yuan,et al.  Endothelial-to-mesenchymal transition contributes to cardiac fibrosis , 2007, Nature Medicine.

[107]  C Michael Stein,et al.  Non-steroidal anti-inflammatory drugs and risk of serious coronary heart disease: an observational cohort study , 2002, The Lancet.

[108]  W Grossman,et al.  Wall stress and patterns of hypertrophy in the human left ventricle. , 1975, The Journal of clinical investigation.

[109]  J. Ge,et al.  Rationale and design of the β‐blocker in heart failure with normal left ventricular ejection fraction (β‐PRESERVE) study , 2010, European journal of heart failure.

[110]  P. Kistler,et al.  Myocardial fibrosis predicts appropriate device therapy in patients with implantable cardioverter-defibrillators for primary prevention of sudden cardiac death. , 2011, Journal of the American College of Cardiology.

[111]  H. Sostman,et al.  Intact systolic left ventricular function in clinical congestive heart failure. , 1985, The American journal of cardiology.

[112]  Anindita Das,et al.  Anti-Inflammatory and Cardioprotective Effects of Tadalafil in Diabetic Mice , 2012, PloS one.

[113]  S. Houser,et al.  Abnormalities of calcium cycling in the hypertrophied and failing heart. , 2000, Journal of molecular and cellular cardiology.

[114]  B. Pitt,et al.  Molecular imaging of interstitial alterations in remodeling myocardium after myocardial infarction. , 2008, Journal of the American College of Cardiology.

[115]  C. Lavie,et al.  Body composition and prognosis in chronic systolic heart failure: the obesity paradox. , 2002, The American journal of cardiology.

[116]  S. Majumdar,et al.  Drug treatments for obesity: orlistat, sibutramine, and rimonabant , 2007, The Lancet.

[117]  T. Prolla,et al.  Age‐dependent cardiomyopathy in mitochondrial mutator mice is attenuated by overexpression of catalase targeted to mitochondria , 2010, Aging cell.

[118]  R. Kloner,et al.  An update on cardioprotection: a review of the latest adjunctive therapies to limit myocardial infarction size in clinical trials. , 2012, Journal of the American College of Cardiology.

[119]  J. Cleland,et al.  The effects of the cardiac myosin activator, omecamtiv mecarbil, on cardiac function in systolic heart failure: a double-blind, placebo-controlled, crossover, dose-ranging phase 2 trial , 2011, The Lancet.

[120]  M. Keane,et al.  Reverse remodelling in heart failure with cardiac resynchronisation therapy , 2005, Heart.

[121]  D. Rosenbaum,et al.  Transmural Electrophysiological Heterogeneities Underlying Arrhythmogenesis in Heart Failure , 2003, Circulation research.

[122]  H. Ushikoshi,et al.  Autophagic cardiomyocyte death in cardiomyopathic hamsters and its prevention by granulocyte colony-stimulating factor. , 2006, The American journal of pathology.

[123]  L. Mestroni,et al.  Truncations of titin causing dilated cardiomyopathy. , 2012, The New England journal of medicine.

[124]  O. Nielsen,et al.  Prevalence and prognosis of heart failure with preserved ejection fraction and elevated N‐terminal pro brain natriuretic peptide: a 10‐year analysis from the Copenhagen Hospital Heart Failure Study , 2012, European journal of heart failure.

[125]  M. Weis,et al.  Cardiac allograft vasculopathy: recent developments. , 2008, Circulation.

[126]  C. Hayward,et al.  Gender-related differences in the central arterial pressure waveform. , 1997, Journal of the American College of Cardiology.

[127]  Stephan Rohr,et al.  Electrotonic Modulation of Cardiac Impulse Conduction by Myofibroblasts , 2006, Circulation research.

[128]  G. Lamas,et al.  Impact of Collateral Flow to the Occluded Infarct-Related Artery on Clinical Outcomes in Patients With Recent Myocardial Infarction: A Report From the Randomized Occluded Artery Trial , 2010, Circulation.

[129]  E. Marbán,et al.  Regenerative Potential of Cardiosphere-Derived Cells Expanded From Percutaneous Endomyocardial Biopsy Specimens , 2007, Circulation.

[130]  Jose H. Flores-Arredondo,et al.  Immune Modulation in Heart Failure: Past Challenges and Future Hopes , 2011, Current Heart Failure Reports.

[131]  Marcus F Stoddard,et al.  Cardiac stem cells in patients with ischaemic cardiomyopathy (SCIPIO): initial results of a randomised phase 1 trial , 2011, The Lancet.

[132]  Barry Greenberg,et al.  Calcium Upregulation by Percutaneous Administration of Gene Therapy in Cardiac Disease (CUPID): A Phase 2 Trial of Intracoronary Gene Therapy of Sarcoplasmic Reticulum Ca2+-ATPase in Patients With Advanced Heart Failure , 2011, Circulation.

[133]  Fatih Kocabaş,et al.  Meis1 regulates postnatal cardiomyocyte cell cycle arrest , 2013, Nature.

[134]  B. Blaxall,et al.  Taking the heart failure battle inside the cell: small molecule targeting of Gβγ subunits. , 2011, Journal of molecular and cellular cardiology.

[135]  Li Qian,et al.  In vivo reprogramming of murine cardiac fibroblasts into induced cardiomyocytes , 2011, Nature.

[136]  N. Farman,et al.  Prerequisite for cardiac aldosterone action. Mineralocorticoid receptor and 11 beta-hydroxysteroid dehydrogenase in the human heart. , 1995, Circulation.

[137]  L. Goldberg Heart Failure , 2010, Annals of Internal Medicine.

[138]  M. Packer Do β-blockers prolong survival in heart failure only by inhibiting the β1-receptor? A perspective on the results of the COMET trial , 2003 .

[139]  Andrew R Coggan,et al.  Absence of an effect of liposuction on insulin action and risk factors for coronary heart disease. , 2004, The New England journal of medicine.

[140]  Dudley J Pennell,et al.  Cardiovascular magnetic resonance, fibrosis, and prognosis in dilated cardiomyopathy. , 2006, Journal of the American College of Cardiology.

[141]  G. Novo,et al.  The role of the renin-angiotensin system in atrial fibrillation and the therapeutic effects of ACE-Is and ARBS. , 2008, British journal of clinical pharmacology.

[142]  Michael D. Schneider,et al.  Cardiac progenitor cells from adult myocardium: Homing, differentiation, and fusion after infarction , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[143]  R. Arena,et al.  PDE5 Inhibition With Sildenafil Improves Left Ventricular Diastolic Function, Cardiac Geometry, and Clinical Status in Patients With Stable Systolic Heart Failure: Results of a 1-Year, Prospective, Randomized, Placebo-Controlled Study , 2011, Circulation. Heart failure.

[144]  J. Ménard,et al.  Aldosterone Synthase Inhibition With LCI699: A Proof-of-Concept Study in Patients With Primary Aldosteronism , 2010, Hypertension.

[145]  B. Howard,et al.  Vascular Biomarkers in the Prediction of Clinical Cardiovascular Disease: The Strong Heart Study , 2012, Hypertension.

[146]  M. Cohen,et al.  Cardiac morphology and left ventricular function in normotensive morbidly obese patients with and without congestive heart failure, and effect of weight loss. , 1997, The American journal of cardiology.

[147]  G. Sanz,et al.  Clinical implications of increased plasma angiotensin II despite ACE inhibitor therapy in patients with congestive heart failure. , 2000, European heart journal.

[148]  K. Swedberg,et al.  Short-term clinical effects of tolvaptan, an oral vasopressin antagonist, in patients hospitalized for heart failure: the EVEREST Clinical Status Trials. , 2007, JAMA.

[149]  Joseph A. Hill,et al.  Electrical remodeling in cardiac hypertrophy. , 2003, Trends in cardiovascular medicine.

[150]  S. Goldstein,et al.  Chronic therapy with metoprolol attenuates cardiomyocyte apoptosis in dogs with heart failure. , 2000, Journal of the American College of Cardiology.

[151]  W. Koch,et al.  Genetic Alterations That Inhibit In Vivo Pressure-Overload Hypertrophy Prevent Cardiac Dysfunction Despite Increased Wall Stress , 2002, Circulation.

[152]  Joseph A. Hill,et al.  Calcineurin-dependent ion channel regulation in heart. , 2014, Trends in cardiovascular medicine.

[153]  A. Khera,et al.  Forecasting the Future of Cardiovascular Disease in the United States: A Policy Statement From the American Heart Association , 2011, Circulation.

[154]  J. Tamargo,et al.  Novel therapeutic targets for the treatment of heart failure , 2011, Nature Reviews Drug Discovery.

[155]  T. Asano,et al.  Distinct Roles of Autophagy in the Heart During Ischemia and Reperfusion: Roles of AMP-Activated Protein Kinase and Beclin 1 in Mediating Autophagy , 2007, Circulation research.

[156]  R. Burt,et al.  Clinical applications of blood-derived and marrow-derived stem cells for nonmalignant diseases. , 2008, JAMA.

[157]  E. McNally,et al.  Genetic mutations and mechanisms in dilated cardiomyopathy. , 2013, The Journal of clinical investigation.

[158]  Deepak M. Gupta,et al.  A nonviral minicircle vector for deriving human iPS cells , 2010, Nature Methods.

[159]  M. Berlan,et al.  Natriuretic peptide-dependent lipolysis in fat cells is a primate specificity. , 2002, American journal of physiology. Regulatory, integrative and comparative physiology.

[160]  Francis G Spinale,et al.  Myocardial matrix remodeling and the matrix metalloproteinases: influence on cardiac form and function. , 2007, Physiological reviews.

[161]  KenjiHayakawa,et al.  Inhibition of Granulation Tissue Cell Apoptosis During the Subacute Stage of Myocardial Infarction Improves Cardiac Remodeling and Dysfunction at the Chronic Stage , 2003 .

[162]  R. Shannon,et al.  Glucagon‐like Peptide‐1 and Myocardial Protection: More than Glycemic Control , 2009, Clinical cardiology.

[163]  P. Galuppo,et al.  Improvement in Left Ventricular Remodeling by the Endothelial Nitric Oxide Synthase Enhancer AVE9488 After Experimental Myocardial Infarction , 2008, Circulation.

[164]  Richard T. Lee,et al.  Mammalian Heart Renewal by Preexisting Cardiomyocytes , 2012, Nature.

[165]  P. Anversa,et al.  Angiotensin II Induces Apoptosis of Adult Ventricular MyocytesIn Vitro , 1997 .

[166]  D. Yellon,et al.  Leptin, the obesity‐associated hormone, exhibits direct cardioprotective effects , 2006, British journal of pharmacology.

[167]  G. Biondi-Zoccai,et al.  Impact of intracoronary cell therapy on left ventricular function in the setting of acute myocardial infarction: a collaborative systematic review and meta-analysis of controlled clinical trials. , 2007, Journal of the American College of Cardiology.

[168]  I. Komuro,et al.  p53-induced inhibition of Hif-1 causes cardiac dysfunction during pressure overload , 2007, Nature.

[169]  E. Marbán,et al.  Direct comparison of different stem cell types and subpopulations reveals superior paracrine potency and myocardial repair efficacy with cardiosphere-derived cells. , 2012, Journal of the American College of Cardiology.

[170]  S. Felix,et al.  Immunoadsorption in dilated cardiomyopathy: 6-month results from a randomized study. , 2006, American heart journal.

[171]  C. G. Blomqvist,et al.  Cardiac atrophy after bed rest and spaceflight. , 2001, Journal of applied physiology.

[172]  D. Sica Pharmacokinetics and Pharmacodynamics of Mineralocorticoid Blocking Agents and their Effects on Potassium Homeostasis , 2005, Heart Failure Reviews.

[173]  R. McKelvie,et al.  Prevalence and Significance of Alterations in Cardiac Structure and Function in Patients With Heart Failure and a Preserved Ejection Fraction , 2011, Circulation.

[174]  Louis Hue,et al.  The Randle cycle revisited: a new head for an old hat. , 2009, American journal of physiology. Endocrinology and metabolism.

[175]  M. Burch,et al.  Hypertrophic cardiomyopathy. , 1994, Archives of disease in childhood.

[176]  P. Elliott,et al.  Prospective Familial Assessment in Dilated Cardiomyopathy: Cardiac Autoantibodies Predict Disease Development in Asymptomatic Relatives , 2006, Circulation.

[177]  Katherine C. Wu,et al.  Late gadolinium enhancement by cardiovascular magnetic resonance heralds an adverse prognosis in nonischemic cardiomyopathy. , 2008, Journal of the American College of Cardiology.

[178]  Caleb E. Finch,et al.  Evolution of the human lifespan and diseases of aging: Roles of infection, inflammation, and nutrition , 2009, Proceedings of the National Academy of Sciences.

[179]  T. Ichisaka,et al.  Generation of germline-competent induced pluripotent stem cells , 2007, Nature.

[180]  Daniel Berman,et al.  Intracoronary cardiosphere-derived cells for heart regeneration after myocardial infarction (CADUCEUS): a prospective, randomised phase 1 trial , 2012, The Lancet.

[181]  P. D. del Nido,et al.  Promoting angiogenesis protects severely hypertrophied hearts from ischemic injury. , 2004, The Annals of thoracic surgery.

[182]  P. Poole‐Wilson,et al.  The cardiac component of cardiac cachexia. , 2002, American heart journal.

[183]  A. Cohen-Solal,et al.  Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS). , 2005, European heart journal.

[184]  S. Solomon,et al.  Effects of the Oral Direct Renin Inhibitor Aliskiren in Patients With Symptomatic Heart Failure , 2008, Circulation. Heart failure.

[185]  Gregg S. Pressman,et al.  Impact of obesity on total and cardiovascular mortality—fat or fiction? , 2011, Nature Reviews Cardiology.

[186]  M. Packer Can brain natriuretic peptide be used to guide the management of patients with heart failure and a preserved ejection fraction? The wrong way to identify new treatments for a nonexistent disease. , 2011, Circulation. Heart failure.

[187]  M. Maurer,et al.  Heart Failure with Preserved Ejection Fraction: Persistent Diagnosis, Therapeutic Enigma , 2011, Current cardiovascular risk reports.

[188]  J. Elmquist,et al.  Adipose Tissue Biology and Cardiomyopathy: Translational Implications , 2012, Circulation research.

[189]  Amir Lerman,et al.  Global cardiovascular reserve dysfunction in heart failure with preserved ejection fraction. , 2010, Journal of the American College of Cardiology.

[190]  G. Sweeney,et al.  Cardiac remodeling in obesity. , 2008, Physiological reviews.

[191]  G. Taffet,et al.  Aging-related defects are associated with adverse cardiac remodeling in a mouse model of reperfused myocardial infarction. , 2008, Journal of the American College of Cardiology.

[192]  R. Stewart,et al.  Induced Pluripotent Stem Cell Lines Derived from Human Somatic Cells , 2007, Science.

[193]  B. Rothermel,et al.  Autophagy in load-induced heart disease. , 2008, Circulation research.

[194]  K. Pandey Guanylyl cyclase / atrial natriuretic peptide receptor-A: role in the pathophysiology of cardiovascular regulation. , 2011, Canadian journal of physiology and pharmacology.

[195]  J. Loscalzo,et al.  Cardiomyogenesis in the Aging and Failing Human Heart , 2012, Circulation.

[196]  Zeneng Wang,et al.  Intestinal Microbial Metabolism of Phosphatidylcholine and Cardiovascular Risk , 2013 .

[197]  H. N. Sabbah,et al.  Repolarization abnormalities in cardiomyocytes of dogs with chronic heart failure: role of sustained inward current , 1999, Cellular and Molecular Life Sciences CMLS.

[198]  Ajit Varki,et al.  alpha 2-6-Linked sialic acids on N-glycans modulate carcinoma differentiation in vivo. , 2008, Cancer research.

[199]  Wojciech Zareba,et al.  Cardiac-resynchronization therapy for the prevention of heart-failure events. , 2009, The New England journal of medicine.

[200]  Hugh Calkins,et al.  Prophylactic defibrillator implantation in patients with nonischemic dilated cardiomyopathy. , 2004, The New England journal of medicine.

[201]  P. Sugden An overview of endothelin signaling in the cardiac myocyte. , 2003, Journal of molecular and cellular cardiology.

[202]  N. Wong,et al.  Molecular imaging for efficacy of pharmacologic intervention in myocardial remodeling. , 2009, JACC. Cardiovascular imaging.

[203]  Brandon K. Fornwalt,et al.  Agreement Is Poor Among Current Criteria Used to Define Response to Cardiac Resynchronization Therapy , 2010, Circulation.

[204]  Chang Yao,et al.  Modification of Collagen Matrices for Enhancing Angiogenesis , 2005, Cells Tissues Organs.

[205]  Joseph A. Hill,et al.  Spironolactone Therapy is Associated with Reduced Ventricular Tachycardia Rate in Patients with Cardiomyopathy , 2011, Pacing and clinical electrophysiology : PACE.

[206]  E. Olson,et al.  Reversibility of Adverse, Calcineurin-Dependent Cardiac Remodeling , 2011, Circulation research.

[207]  S. Frøland,et al.  Complement Activation in Patients With Congestive Heart Failure: Effect of High-Dose Intravenous Immunoglobulin Treatment , 2001, Circulation.

[208]  I. Benjamin,et al.  Autophagy is an adaptive response in desmin-related cardiomyopathy , 2007, Proceedings of the National Academy of Sciences.

[209]  P. Galuppo,et al.  Novel therapeutic approaches to post-infarction remodelling. , 2012, Cardiovascular research.

[210]  M. Beer,et al.  Impact of Myocardial Fibrosis in Patients With Symptomatic Severe Aortic Stenosis , 2009, Circulation.

[211]  D. Kass,et al.  Cardiovascular features of heart failure with preserved ejection fraction versus nonfailing hypertensive left ventricular hypertrophy in the urban Baltimore community: the role of atrial remodeling/dysfunction. , 2007, Journal of the American College of Cardiology.

[212]  D. Mikhailidis,et al.  Should a statin be prescribed to every patient with heart failure? , 2008, Heart Failure Reviews.

[213]  W. Paulus,et al.  Heart failure with preserved ejection fraction: pathophysiology, diagnosis, and treatment. , 2011, European heart journal.

[214]  W. Pu,et al.  Epicardial epithelial-to-mesenchymal transition in injured heart , 2011, Journal of cellular and molecular medicine.

[215]  D. Berry,et al.  Bayesian adaptive trial design in acute heart failure syndromes: moving beyond the mega trial. , 2012, American heart journal.

[216]  Marc A Pfeffer,et al.  Controversies in ventricular remodelling , 2006, The Lancet.

[217]  Guido Kroemer,et al.  The end of autophagic cell death? , 2012, Autophagy.

[218]  E. Olson,et al.  Transient Regenerative Potential of the Neonatal Mouse Heart , 2011, Science.

[219]  R. Holubkov,et al.  Controlled Trial of Intravenous Immune Globulin in Recent-Onset Dilated Cardiomyopathy , 2001, Circulation.

[220]  G. Baumann,et al.  Potential role of humoral immunity in cardiac dysfunction of patients suffering from dilated cardiomyopathy. , 2004, Journal of the American College of Cardiology.

[221]  E. Olson,et al.  Cardiac plasticity. , 2008, The New England journal of medicine.

[222]  S. Nitter‐Hauge,et al.  Immunomodulating Therapy With Intravenous Immunoglobulin in Patients With Chronic Heart Failure , 2001, Circulation.

[223]  B. Liu,et al.  Therapeutic effect of MG-132 on diabetic cardiomyopathy is associated with its suppression of proteasomal activities: roles of Nrf2 and NF-κB. , 2013, American journal of physiology. Heart and circulatory physiology.

[224]  M C Oz,et al.  Long-term use of a left ventricular assist device for end-stage heart failure. , 2001, The New England journal of medicine.

[225]  R. W. Joyner,et al.  Remodeling of Early-Phase Repolarization: A Mechanism of Abnormal Impulse Conduction in Heart Failure , 2006, Circulation.

[226]  J. Fildes,et al.  The immune system and chronic heart failure: is the heart in control? , 2009, Journal of the American College of Cardiology.

[227]  V. Roger,et al.  Pulmonary hypertension in heart failure with preserved ejection fraction: a community-based study. , 2009, Journal of the American College of Cardiology.

[228]  H. Krumholz,et al.  The obesity paradox: body mass index and outcomes in patients with heart failure. , 2005, Archives of internal medicine.

[229]  D. Levy,et al.  Predictors of New-Onset Heart Failure: Differences in Preserved Versus Reduced Ejection Fraction , 2013, Circulation. Heart failure.

[230]  E. D. du Toit,et al.  Obesity improves myocardial ischaemic tolerance and RISK signalling in insulin-insensitive rats , 2012, Disease Models & Mechanisms.

[231]  R. Bassel-Duby,et al.  Diminished Cardiac Fibrosis in Heart Failure is Associated with Altered Ventricular Arrhythmia Phenotype , 2010, Journal of cardiovascular electrophysiology.

[232]  C. Heeschen,et al.  Selective functional exhaustion of hematopoietic progenitor cells in the bone marrow of patients with postinfarction heart failure. , 2007, Journal of the American College of Cardiology.

[233]  P. Vardas,et al.  Effects of the long‐term administration of nebivolol on the clinical symptoms, exercise capacity, and left ventricular function of patients with diastolic dysfunction: results of the ELANDD study , 2012, European journal of heart failure.

[234]  I. Shiojima,et al.  Disruption of coordinated cardiac hypertrophy and angiogenesis contributes to the transition to heart failure. , 2005, The Journal of clinical investigation.

[235]  J. Fang,et al.  Rise of the machines--left ventricular assist devices as permanent therapy for advanced heart failure. , 2009, The New England journal of medicine.

[236]  S. Grundy Pre-diabetes, metabolic syndrome, and cardiovascular risk. , 2012, Journal of the American College of Cardiology.

[237]  J. McMurray,et al.  Long-term effects of darusentan on left-ventricular remodelling and clinical outcomes in the EndothelinA Receptor Antagonist Trial in Heart Failure (EARTH): randomised, double-blind, placebo-controlled trial , 2004, The Lancet.

[238]  R. Kitsis,et al.  A mechanistic role for cardiac myocyte apoptosis in heart failure. , 2003, The Journal of clinical investigation.

[239]  V. Hasselblad,et al.  Tezosentan in patients with acute heart failure and acute coronary syndromes: results of the Randomized Intravenous TeZosentan Study (RITZ-4). , 2003, Journal of the American College of Cardiology.

[240]  J. McMurray,et al.  Eplerenone in patients with systolic heart failure and mild symptoms. , 2011, The New England journal of medicine.

[241]  M. Quiñones,et al.  Simvastatin Induces Regression of Cardiac Hypertrophy and Fibrosis and Improves Cardiac Function in a Transgenic Rabbit Model of Human Hypertrophic Cardiomyopathy , 2001, Circulation.

[242]  E. Olson,et al.  Muscle : fundamental biology and mechanisms of disease , 2012 .

[243]  Kevin Kit Parker,et al.  Time-Warped Comparison of Gene Expression in Adaptive and Maladaptive Cardiac Hypertrophy , 2009, Circulation. Cardiovascular genetics.

[244]  Gissi-Hf Investigators Effect of rosuvastatin in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial , 2008, The Lancet.

[245]  S. Liggett Pharmacogenomics of beta1-adrenergic receptor polymorphisms in heart failure. , 2010, Heart failure clinics.

[246]  Yuyang Sun,et al.  Ca2+/Calmodulin-dependent Protein Kinase II-dependent Remodeling of Ca2+ Current in Pressure Overload Heart Failure* , 2008, Journal of Biological Chemistry.

[247]  V. Vedantham,et al.  Direct Reprogramming of Fibroblasts into Functional Cardiomyocytes by Defined Factors , 2010, Cell.

[248]  Mark D. Huffman,et al.  Heart disease and stroke statistics--2013 update: a report from the American Heart Association. , 2013, Circulation.

[249]  J. Mant,et al.  Management of Chronic Heart Failure in Adults: Synopsis of the National Institute for Health and Clinical Excellence Guideline , 2011, Annals of Internal Medicine.

[250]  D. Kass,et al.  Mechanisms of Enhanced &bgr;-Adrenergic Reserve From Cardiac Resynchronization Therapy , 2009, Circulation.

[251]  Sachil Shah Review: Heart failure with preserved ejection fraction in African Americans. , 2012, Ethnicity & disease.

[252]  J. Schneider,et al.  Targeting native adult heart progenitors with cardiogenic small molecules. , 2012, ACS chemical biology.

[253]  B. Howard,et al.  Sex differences in obesity-related changes in left ventricular morphology: the Strong Heart Study , 2011, Journal of hypertension.

[254]  E. J. Brown,et al.  The effect of digoxin on mortality and morbidity in patients with heart failure. , 1997, The New England journal of medicine.

[255]  H. McLeod,et al.  Genetic tailoring of pharmacotherapy in heart failure: optimize the old, while we wait for something new. , 2012, Journal of cardiac failure.

[256]  G. Dwivedi,et al.  Heart failure with preserved ejection fraction: current understanding and emerging concepts , 2013, Current opinion in cardiology.

[257]  Arantxa González,et al.  Losartan-Dependent Regression of Myocardial Fibrosis Is Associated With Reduction of Left Ventricular Chamber Stiffness in Hypertensive Patients , 2002, Circulation.

[258]  D. Kass,et al.  Ionic mechanism of action potential prolongation in ventricular myocytes from dogs with pacing-induced heart failure. , 1996, Circulation research.

[259]  David M Kent,et al.  Limitations of applying summary results of clinical trials to individual patients: the need for risk stratification. , 2007, JAMA.

[260]  J. Pepper,et al.  Midwall fibrosis is an independent predictor of mortality in patients with aortic stenosis. , 2011, Journal of the American College of Cardiology.

[261]  G. Dorn Novel pharmacotherapies to abrogate postinfarction ventricular remodeling , 2009, Nature Reviews Cardiology.

[262]  R. Johnstone,et al.  The genetic basis of family conflict resolution in mice , 2003, Nature.

[263]  I. Anand,et al.  Long-term caspase inhibition ameliorates apoptosis, reduces myocardial troponin-I cleavage, protects left ventricular function, and attenuates remodeling in rats with myocardial infarction. , 2004, Journal of the American College of Cardiology.

[264]  R. Sarangapani,et al.  Pharmacokinetics and Pharmacodynamics of LCZ696, a Novel Dual‐Acting Angiotensin Receptor—Neprilysin Inhibitor (ARNi) , 2010, Journal of clinical pharmacology.

[265]  Ziya Kaya,et al.  Autoantibodies in heart failure and cardiac dysfunction. , 2012, Circulation research.

[266]  A. Mihailidou,et al.  Low-Dose Spironolactone Prevents Apoptosis Repressor With Caspase Recruitment Domain Degradation During Myocardial Infarction , 2012, Hypertension.

[267]  S. Ball,et al.  Angiotensin II type-1 receptor activation in the adult heart causes blood pressure-independent hypertrophy and cardiac dysfunction. , 2009, Cardiovascular research.

[268]  W. Koch,et al.  Targeted &bgr;-Adrenergic Receptor Kinase (&bgr;ARK1) Inhibition by Gene Transfer in Failing Human Hearts , 2004 .

[269]  E. Olson,et al.  Suppression of Class I and II Histone Deacetylases Blunts Pressure-Overload Cardiac Hypertrophy , 2006, Circulation.

[270]  Joshua M Hare,et al.  Comparison of allogeneic vs autologous bone marrow–derived mesenchymal stem cells delivered by transendocardial injection in patients with ischemic cardiomyopathy: the POSEIDON randomized trial. , 2012, JAMA.

[271]  Shokei Kim,et al.  Angiotensin II induces cardiac phenotypic modulation and remodeling in vivo in rats. , 1995, Hypertension.

[272]  D. Bers,et al.  Ca2+/Calmodulin–Dependent Protein Kinase Modulates Cardiac Ryanodine Receptor Phosphorylation and Sarcoplasmic Reticulum Ca2+ Leak in Heart Failure , 2005, Circulation research.

[273]  N. Dhalla,et al.  Potential of endothelin-1 and vasopressin antagonists for the treatment of congestive heart failure , 2009, Heart Failure Reviews.

[274]  N. Freemantle,et al.  FASTTRACK : The perindopril in elderly people with chronic heart failure (PEP-CHF) study , 2006 .

[275]  Dariush Mozaffarian,et al.  Red and Processed Meat Consumption and Risk of Incident Coronary Heart Disease, Stroke, and Diabetes Mellitus: A Systematic Review and Meta-Analysis , 2010, Circulation.

[276]  P. Galuppo,et al.  Improvement of Left Ventricular Remodeling and Function by Hydroxymethylglutaryl Coenzyme A Reductase Inhibition With Cerivastatin in Rats With Heart Failure After Myocardial Infarction , 2001, Circulation.

[277]  B. Dahlöf,et al.  Compound 21, the first orally active, selective agonist of the angiotensin type 2 receptor (AT2): implications for AT2 receptor research and therapeutic potential , 2010, Journal of the renin-angiotensin-aldosterone system : JRAAS.

[278]  R. Canby,et al.  Combined cardiac resynchronization and implantable cardioversion defibrillation in advanced chronic heart failure: the MIRACLE ICD Trial. , 2003, JAMA.

[279]  C. Cooper,et al.  Use of oral glucocorticoids and risk of cardiovascular and cerebrovascular disease in a population based case–control study , 2004, Heart.

[280]  The obesity paradox: body mass index and outcomes in patients with heart failure , 2003 .

[281]  D. Burke,et al.  Age-associated activation of epigenetically repressed genes in the mouse. , 2003, Genetics.

[282]  C. Seiler,et al.  The impact of the coronary collateral circulation on mortality: a meta-analysis. , 2012, European heart journal.

[283]  Mohit M. Jain,et al.  Cardiac side population cells: moving toward the center stage in cardiac regeneration. , 2012, Circulation research.